ArticleJournal of clinical and translational hepatology2019

Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China.

Xiaoyuan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.